{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Papachristodoulou A"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["361-372"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10902192"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["85(4)"],"pubmed_abstract":["<h4>Background</h4>The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate whether the efficacy of metformin in PCa is related to the expression status of NKX3.1, a prostate-specific homeobox gene that functions in mitochondria to protect the prostate from aberrant oxidative stress.<h4>Objective</h4>To investigate the relationship of NKX3.1 expression and metformin efficacy in PCa.<h4>Design, setting, and participants</h4>Functional studies were performed in vivo and in vitro in genetically engineered mouse models and human LNCaP cells, and organotypic cultures having normal or reduced/absent levels of NKX3.1. Correlative studies were perfor"],"journal":["European urology"],"pubmed_title":["Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression."],"pmcid":["PMC10902192"],"funding_grant_id":["P20 GM103446","R01 CA233176","P50 CA211024","P01 CA265768","R01 CA173481","K99 CA276713","P30 CA013696"],"pubmed_authors":["De Castro GJ","Heidegger I","Abate-Shen C","Klocker H","Schafer G","Zheng T","Virk RK","Papachristodoulou A","Kim JY","Loda M","Dutta A","McKiernan JM","Benson MC","Laplaca C","Hibshoosh H","Di Bernardo M","Rubin MA","Picech F"],"additional_accession":[]},"is_claimable":false,"name":"Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.","description":"<h4>Background</h4>The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate whether the efficacy of metformin in PCa is related to the expression status of NKX3.1, a prostate-specific homeobox gene that functions in mitochondria to protect the prostate from aberrant oxidative stress.<h4>Objective</h4>To investigate the relationship of NKX3.1 expression and metformin efficacy in PCa.<h4>Design, setting, and participants</h4>Functional studies were performed in vivo and in vitro in genetically engineered mouse models and human LNCaP cells, and organotypic cultures having normal or reduced/absent levels of NKX3.1. Correlative studies were perfor","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-02T18:10:42.494Z","creation":"2025-07-11T03:04:07.851Z"},"accession":"S-EPMC10902192","cross_references":{"pubmed":["37659962"],"doi":["10.1016/j.eururo.2023.07.016"]}}